Information Journal Paper
APA:
Copy. (2018). Anti-CD73 and anti-OX40 immunotherapy coupled with a novel biocompatible enzyme prodrug system for the treatment of recurrent, metastatic ovarian cancer. CANCER LETTERS, 425(-), 174-182. SID. https://sid.ir/paper/754728/en
Vancouver:
Copy. Anti-CD73 and anti-OX40 immunotherapy coupled with a novel biocompatible enzyme prodrug system for the treatment of recurrent, metastatic ovarian cancer. CANCER LETTERS[Internet]. 2018;425(-):174-182. Available from: https://sid.ir/paper/754728/en
IEEE:
Copy, “Anti-CD73 and anti-OX40 immunotherapy coupled with a novel biocompatible enzyme prodrug system for the treatment of recurrent, metastatic ovarian cancer,” CANCER LETTERS, vol. 425, no. -, pp. 174–182, 2018, [Online]. Available: https://sid.ir/paper/754728/en